Literature DB >> 15845461

Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity.

Ernestas Janulionis1, Carolina Sofer, Stephan K Schwander, Denarra Nevels, Barry Kreiswirth, Elena Shashkina, Robert S Wallis.   

Abstract

The initial host response to Mycobacterium tuberculosis is driven by innate immunity. For this study, we examined the ability of 18 recent clinical isolates and 5 reference strains to survive and replicate in the context of host innate immunity by using whole blood culture. Six healthy tuberculin-negative volunteers served as subjects. H(37)Ra showed the least capacity to replicate of any of the strains tested, decreasing in viability 1.3 log CFU during 72 h of whole blood culture, whereas H(37)Rv increased 0.32 log. Clinical isolates varied greatly in their ability to replicate in blood cells, ranging from -0.4 to +0.8 log (P < 0.001). Four showed significantly more growth than H(37)Rv, and one showed significantly reduced growth. Host mechanisms for restricting intracellular mycobacterial growth were more effective during the first 24 h of whole blood culture than during the 24- to 72-h period. Certain mycobacterial isolates appeared preferentially able to withstand host defenses during each of these intervals. Although there was relatively more homogeneity among subjects than among strains, one of the six subjects showed a reduced capacity to restrict intracellular mycobacterial growth due to a defect expressed during the first 24 h of culture. Our findings indicate substantial variability in the capacity of clinical tuberculosis isolates to replicate in host cells in the face of innate host immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15845461      PMCID: PMC1087323          DOI: 10.1128/IAI.73.5.2595-2601.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity.

Authors:  Daniel F Hoft; Shewangizaw Worku; Beate Kampmann; Christopher C Whalen; Jerrold J Ellner; Christina S Hirsch; Robin B Brown; Rhonda Larkin; Qing Li; Hyun Yun; Richard F Silver
Journal:  J Infect Dis       Date:  2002-10-23       Impact factor: 5.226

2.  Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis.

Authors:  Seon-Hee Cheon; Beate Kampmann; Amy G Hise; Manijeh Phillips; Ho-Yeon Song; Katherine Landen; Qing Li; Rhonda Larkin; Jerrold J Ellner; Richard F Silver; Daniel F Hoft; Robert S Wallis
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

3.  Whole blood bactericidal activity during treatment of pulmonary tuberculosis.

Authors:  Robert S Wallis; Solange A Vinhas; John L Johnson; Fabíola C Ribeiro; Moisés Palaci; Renata L Peres; Ricardo T Sá; Reynaldo Dietze; Allan Chiunda; Kathleen Eisenach; Jerrold J Ellner
Journal:  J Infect Dis       Date:  2003-01-06       Impact factor: 5.226

4.  Persistence of a highly resistant strain of tuberculosis in New York City during 1990-1999.

Authors:  Sonal S Munsiff; Beth Nivin; Galit Sacajiu; Barun Mathema; Pablo Bifani; Barry N Kreiswirth
Journal:  J Infect Dis       Date:  2003-07-18       Impact factor: 5.226

5.  Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta.

Authors:  C Manca; L Tsenova; A Bergtold; S Freeman; M Tovey; J M Musser; C E Barry; V H Freedman; G Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

6.  Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment.

Authors:  R S Wallis; M Perkins; M Phillips; M Joloba; B Demchuk; A Namale; J L Johnson; D Williams; K Wolski; L Teixeira; R Dietze; R D Mugerwa; K Eisenach; J J Ellner
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

7.  A whole blood bactericidal assay for tuberculosis.

Authors:  R S Wallis; M Palaci; S Vinhas; A G Hise; F C Ribeiro; K Landen; S H Cheon; H Y Song; M Phillips; R Dietze; J J Ellner
Journal:  J Infect Dis       Date:  2001-03-08       Impact factor: 5.226

8.  Differences in rate and variability of intracellular growth of a panel of Mycobacterium tuberculosis clinical isolates within a human monocyte model.

Authors:  Qing Li; Christopher C Whalen; Jeffrey M Albert; Rhonda Larkin; Lynn Zukowski; M Donald Cave; Richard F Silver
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

9.  Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils.

Authors:  Kevin O Kisich; Michael Higgins; Gill Diamond; Leonid Heifets
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

10.  Drug tolerance in Mycobacterium tuberculosis.

Authors:  R S Wallis; S Patil; S H Cheon; K Edmonds; M Phillips; M D Perkins; M Joloba; A Namale; J L Johnson; L Teixeira; R Dietze; S Siddiqi; R D Mugerwa; K Eisenach; J J Ellner
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

View more
  8 in total

1.  Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.

Authors:  Robert S Wallis; Wesley Jakubiec; Vikas Kumar; Gabriella Bedarida; Annette Silvia; Darcy Paige; Tong Zhu; Mark Mitton-Fry; Lynn Ladutko; Sheldon Campbell; Paul F Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis.

Authors:  Tong Zhu; Sven O Friedrich; Andreas Diacon; Robert S Wallis
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

3.  Microarray analysis of Mycobacterium tuberculosis-infected monocytes reveals IL26 as a new candidate gene for tuberculosis susceptibility.

Authors:  José M Guerra-Laso; Sara Raposo-García; Silvia García-García; Cristina Diez-Tascón; Octavio M Rivero-Lezcano
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

4.  Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture.

Authors:  Elizabeth P Harausz; Keith A Chervenak; Caryn E Good; Michael R Jacobs; Robert S Wallis; Manuel Sanchez-Felix; W Henry Boom
Journal:  Tuberculosis (Edinb)       Date:  2016-03-22       Impact factor: 3.131

5.  Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis.

Authors:  Robert S Wallis; Solange Vinhas; Ernestas Janulionis
Journal:  Tuberculosis (Edinb)       Date:  2009-03-24       Impact factor: 3.131

6.  Mycobacterial Growth Inhibition Assay (MGIA) as a Host Directed Diagnostic Tool for the Evaluation of the Immune Response in Subjects Living With Type 2 Diabetes Mellitus.

Authors:  Miriam Bobadilla-Del-Valle; Francisco Leal-Vega; Pedro Torres-Gonzalez; Anabel Ordaz-Vazquez; Maria de Lourdes Garcia-Garcia; Ma de Los Angeles Tovar-Vargas; Guadalupe Delgado-Sanchez; Paola Del Carmen Guerra De Blas; Robert S Wallis; Alfredo Ponce-De-León; José Sifuentes-Osornio
Journal:  Front Cell Infect Microbiol       Date:  2021-05-18       Impact factor: 5.293

7.  Presence of RD149 deletions in M. tuberculosis Central Asian Strain 1 isolates affect growth and TNFα induction in THP-1 monocytes.

Authors:  Akbar Kanji; Zahra Hasan; Mehnaz Tanveer; Raunaq Mahboob; Sana Jafri; Rumina Hasan
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

8.  Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.

Authors:  Robert S Wallis; Wesley Jakubiec; Mark Mitton-Fry; Lynn Ladutko; Sheldon Campbell; Darcy Paige; Annette Silvia; Paul F Miller
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.